Raymond James & Associates’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $238M | Sell |
8,209,415
-349,305
| -4% | -$10.2M | 0.14% | 123 |
|
|
2024
Q2 | $239M | Sell |
8,558,720
-204,765
| -2% | -$5.64M | 0.16% | 106 |
|
|
2024
Q1 | $243M | Buy |
8,763,485
+925,960
| +12% | +$25.7M | 0.16% | 102 |
|
|
2023
Q4 | $226M | Sell |
7,837,525
-771,857
| -9% | -$23.3M | 0.17% | 106 |
|
|
2023
Q3 | $286M | Sell |
8,609,382
-135,019
| -2% | -$4.77M | 0.24% | 73 |
|
|
2023
Q2 | $321M | Sell |
8,744,401
-109,770
| -1% | -$4.27M | 0.26% | 68 |
|
|
2023
Q1 | $361M | Buy |
8,854,171
+311,509
| +4% | +$13.5M | 0.31% | 59 |
|
|
2022
Q4 | $438M | Buy |
8,542,662
+348,547
| +4% | +$16.7M | 0.4% | 44 |
|
|
2022
Q3 | $359M | Buy |
8,194,115
+164,241
| +2% | +$7.98M | 0.36% | 49 |
|
|
2022
Q2 | $421M | Buy |
8,029,874
+74,191
| +0.9% | +$3.78M | 0.41% | 42 |
|
|
2022
Q1 | $412M | Buy |
7,955,683
+543,445
| +7% | +$28.2M | 0.35% | 54 |
|
|
2021
Q4 | $438M | Sell |
7,412,238
-151,716
| -2% | -$7.52M | 0.35% | 53 |
|
|
2021
Q3 | $325M | Sell |
7,563,954
-1,147,412
| -13% | -$50.8M | 0.29% | 62 |
|
|
2021
Q2 | $341M | Buy |
8,711,366
+558,427
| +7% | +$21.7M | 0.31% | 57 |
|
|
2021
Q1 | $295M | Sell |
8,152,939
-660,488
| -7% | -$23.5M | 0.3% | 59 |
|
|
2020
Q4 | $324M | Sell |
8,813,427
-1,376,598
| -14% | -$50.5M | 0.36% | 52 |
|
|
2020
Q3 | $355M | Sell |
10,190,025
-829,251
| -8% | -$29.1M | 0.44% | 42 |
|
|
2020
Q2 | $342M | Sell |
11,019,276
-4,509,516
| -29% | -$153M | 0.46% | 38 |
|
|
2020
Q1 | $481M | Buy |
15,528,792
+344,821
| +2% | +$11.7M | 0.76% | 17 |
|
|
2019
Q4 | $564M | Buy |
15,183,971
+1,936,661
| +15% | +$69M | 0.72% | 21 |
|
|
2019
Q3 | $452M | Buy |
13,247,310
+2,087,187
| +19% | +$75.9M | 0.63% | 21 |
|
|
2019
Q2 | $459M | Buy |
11,160,123
+811,263
| +8% | +$32.2M | 0.66% | 21 |
|
|
2019
Q1 | $417M | Sell |
10,348,860
-356,503
| -3% | -$14.3M | 0.63% | 21 |
|
|
2018
Q4 | $443M | Sell |
10,705,363
-774,060
| -7% | -$32.1M | 0.77% | 17 |
|
|
2018
Q3 | $480M | Buy |
11,479,423
+352,468
| +3% | +$13.6M | 0.74% | 15 |
|
|
2018
Q2 | $383M | Buy |
11,126,955
+990,922
| +10% | +$33.9M | 0.64% | 20 |
|
|
2018
Q1 | $341M | Buy |
10,136,033
+423,351
| +4% | +$14.6M | 0.61% | 20 |
|
|
2017
Q4 | $334M | Buy |
9,712,682
+383,178
| +4% | +$13.1M | 0.61% | 21 |
|
|
2017
Q3 | $316M | Buy |
9,329,504
+349,920
| +4% | +$11.2M | 0.63% | 20 |
|
|
2017
Q2 | $286M | Buy |
8,979,584
+531,109
| +6% | +$16.7M | 0.62% | 21 |
|
|
2017
Q1 | $274M | Buy |
8,448,475
+655,119
| +8% | +$20.7M | 0.64% | 20 |
|
|
2016
Q4 | $240M | Buy |
7,793,356
+599,248
| +8% | +$18.3M | 0.61% | 22 |
|
|
2016
Q3 | $231M | Buy |
7,194,108
+1,136,927
| +19% | +$38M | 0.63% | 20 |
|
|
2016
Q2 | $202M | Buy |
6,057,181
+405,656
| +7% | +$12.9M | 0.63% | 20 |
|
|
2016
Q1 | $159M | Sell |
5,651,525
-175,721
| -3% | -$5.02M | 0.54% | 30 |
|
|
2015
Q4 | $178M | Buy |
5,827,246
+673,919
| +13% | +$21.2M | 0.64% | 20 |
|
|
2015
Q3 | $154M | Buy |
5,153,327
+458,374
| +10% | +$14.7M | 0.63% | 21 |
|
|
2015
Q2 | $149M | Buy |
4,694,953
+690,077
| +17% | +$22.5M | 0.57% | 20 |
|
|
2015
Q1 | $132M | Buy |
4,004,876
+438,761
| +12% | +$13.9M | 0.58% | 22 |
|
|
2014
Q4 | $105M | Buy |
3,566,115
+1,204,285
| +51% | +$34.5M | 0.51% | 28 |
|
|
2014
Q3 | $66.3M | Buy |
2,361,830
+40,669
| +2% | +$1.14M | 0.38% | 45 |
|
|
2014
Q2 | $65.4M | Buy |
2,321,161
+114,471
| +5% | +$3.26M | 0.4% | 41 |
|
|
2014
Q1 | $67.2M | Buy |
2,206,690
+91,832
| +4% | +$2.74M | 0.46% | 34 |
|
|
2013
Q4 | $61.5M | Sell |
2,114,858
-217,689
| -9% | -$6.34M | 0.46% | 32 |
|
|
2013
Q3 | $63.6M | Buy |
2,332,547
+122,044
| +6% | +$3.32M | 0.55% | 24 |
|
|
2013
Q2 | $58.7M | Buy |
+2,210,503
| New | +$61.1M | 0.55% | 26 |
|
Other funds holding PFE
Raymond James & Associates's PFE Position: Q3 2024 in Review
Raymond James & Associates reduced its Pfizer (PFE) stake by 4.1% in Q3 2024, selling an estimated $10.2M and leaving 8,209,415 shares worth $238M. The position accounts for 0.14% of the portfolio, ranked #123.
Raymond James & Associates first reported a position in PFE in Q2 2013 and has held it in 46 quarters since. The position peaked at $564M in Q4 2019. 2,909 funds tracked by Wall St. Rank hold PFE as of Q3 2024.
- Raymond James & Associates held 8,209,415 shares of Pfizer worth $238M as of Q3 2024.
- Raymond James & Associates sold 349,305 Pfizer shares in Q3 2024, an estimated $10.2M.
- Pfizer made up 0.14% of Raymond James & Associates's portfolio in Q3 2024, its #123 holding.
- Raymond James & Associates first reported a position in Pfizer in Q2 2013 and has held it in 46 quarters since.
- Raymond James & Associates's Pfizer position peaked at $564M in Q4 2019.
- 2,909 funds tracked by Wall St. Rank held Pfizer as of Q3 2024.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.